Tokyo, Japan – In a watershed moment for regenerative medicine, Japan has approved the world's first therapeutic products derived from induced pluripotent stem (iPS) cells on 6 March 2026. Following a landmark recommendation from a health ministry panel on February 19, 2026, Ministry of Health, Labour and Welfare (MHLW) has now officially passed conditional marketing approval for the two iPS cell-derived therapies, signifying these two pioneering treatments are now ready to make transition from the laboratory into regulated clinical use, offering new hope for patients with severe heart failure and Parkinson’s disease. Developed by the startup Cuorips Inc. and pharmaceutical giant Sumitomo Pharma, these treatments target conditions that have long lacked restorative options. 

The Breakthrough Products: ReHeart and Amchepry

The panel's endorsement covers two distinct allogeneic (donor-derived) products, marking the first time any regulatory body globally has endorsed the commercial sale of such therapies.
ReHeart (Cuorips Inc.): Spun out from research at Osaka University, this therapy is designed for patients with severe heart failure, such as ischemic cardiomyopathy. ReHeart consists of sheets of cardiomyocytes (heart muscle cells) generated from iPS cells. These "cell patches" are surgically applied to the heart's surface to promote vascular regeneration, repair damaged tissue, and improve cardiac function, potentially offering an alternative to organ transplants.

Amchepry (Sumitomo Pharma Co., Ltd. in collaboration with Racthera Inc.): Stemming from research at Kyoto University’s Center for iPS Cell Research and Application (CiRA), this therapy targets advanced Parkinson’s disease. It involves transplanting iPS cell-derived dopaminergic neural progenitor cells into the patient's brain. The goal is to restore dopamine production, thereby improving motor function and addressing the root cause of the disease's debilitating symptoms.

A 'Conditional Approval' Pathway

Consistent with Japan's proactive strategy for advanced therapies, the approval was made under the country's Conditional and Time-Limited Approval pathway for regenerative medicines. This innovative regulatory framework allows for early patient access to promising treatments while their developers continue to gather long-term safety and efficacy data over a period of up to seven years. The clinical evidence submitted to the panel showed acceptable safety profiles and early signs of therapeutic benefit—including improved motor function in Parkinson's patients and enhanced exercise tolerance in heart failure patients—despite the limited sample sizes typical of early-stage cell therapy research.

From Discovery to Reality: A 20-Year Journey

This milestone represents the culmination of a scientific journey that began nearly two decades ago. In 2006, Kyoto University researcher Shinya Yamanaka first successfully generated iPS cells by reprogramming adult cells back into a versatile, pluripotent state—a feat that earned him the Nobel Prize in 2012. Unlike embryonic stem cells, this technology bypasses many ethical concerns and reduces the risk of immune rejection.
"I am very happy to see the first big step toward its societal implementation, 20 years since it was announced," said Yasumasa Yamanaka, Director Emeritus of CiRA, reflecting on the panel's decision.

Why Nerve and Heart Cells Led the Charge?

The approval of these two specific therapies is not a coincidence, nor is it because they were the "easiest" to engineer. In fact, differentiating stem cells into functional, rhythmic heart muscle or complex neurons is a significant bioengineering challenge.
Their position at the front of the line is due to a "Perfect Storm" of medical necessity and scientific readiness:

1. The "Single-Cell, Single-Site" Advantage

Both diseases have a relatively straightforward biological "target" compared to other conditions:

• Parkinson’s Disease: Unlike Alzheimer’s, which affects the entire brain, Parkinson's is primarily caused by the loss of one specific cell type (dopamine-producing neurons) in one specific location (the substantia nigra). There is no need to rebuild the whole brain; just replace those specific "dopamine factories."
• Heart Failure: Post-heart attack, the heart develops "dead zones" of scar tissue. Because heart muscle cells do not naturally regenerate, the objective is clear: replace "dead patches" with "living patches" to restore mechanical pumping power.

In comparison, other cell types are not so straightforward, as outlined in the table below. 

Image source: New Technology Improves Treatment Strategies for Parkinson's Disease - Beijing Time

2. Decades of "Pre-iPSC" Blueprinting

These two fields didn't start from scratch with iPSCs. They followed a "proven map" established over the last 40 years:

• Parkinson’s: Doctors had been experimenting with transplanting fetal brain tissue since the 1980s. While ethically controversial, it proved that if you put new dopamine cells in the right spot, the brain could integrate them. iPSC researchers simply swapped the controversial material for a safer, scalable iPSC-derived version.
• Heart Patches: Scientists had already spent years trying (and often failing) to use bone marrow cells to fix hearts. These early attempts perfected the surgical techniques and "cell sheet" application methods that the iPSC teams eventually used to succeed.

3. The "Visual Proof" in the Lab

From a laboratory standpoint, these two cell types offer a unique advantage: unmistakable proof of success.

• Cardiomyocytes: When you successfully turn an iPSC into a heart cell, it literally starts beating in the petri dish. This provides an immediate signal that the protocol worked.
• Neurons: Nerve cells produce measurable electrical impulses and specific chemicals like dopamine. This allows scientists to "tune" the protocol with high precision.

4. The "Kyoto-Osaka" Factor

The emergence of these two therapies as global "firsts" is also largely attributed to the Kyoto-Osaka Factor—a unique geographic and intellectual concentration of stem cell expertise in the Kansai region of Japan. This region has become the "Silicon Valley" of regenerative medicine, fueled by a 20-year synergy between two powerhouse institutions:

• Kyoto University (The Origin): As the home of Nobel Laureate Shinya Yamanaka, Kyoto’s Center for iPS Cell Research and Application (CiRA) provided the essential "seed" technology. The university focused on the fundamental biology and the creation of allogeneic iPS cell stocks—high-quality, clinical-grade cell banks that could be used for any patient, and together with Dr. Jun Takahashi who has spent 20 years focusing almost exclusively on Parkinson’s diseases, it is a natural that this would be one of the first therapy to emerge.
• Osaka University (The Application): Known for its "Medicine-Engineering" fusion, Osaka researchers has pioneered cell sheet technology. This institution became a world hub for "cell sheet" technology. They were already leaders in using other cell types to make heart patches, so they were the best-positioned to "plug in" iPSCs when the technology became available and hence creating the specialized surgical "patches" used in the ReHeart therapy.

This regional cluster allowed for a seamless transition from basic research to industrial manufacturing, supported by a proactive Japanese government that committed over $1 billion in funding to ensure these two institutions remained at the forefront of the global race.

The Next Frontier: Pancreatic Cells and a Functional Cure for Diabetes

While nerve and heart therapies are the first to reach formal recommendation for approval, we anticipate that the next iPSC therapy application would be in Type 1 Diabetes (T1D). Recent breakthroughs in China and the United States suggest that iPSC-derived pancreatic islet cells could be the next therapy to achieve commercial reality, with clinical trials now demonstrating "functional cures."

1. Chemically Induced iPSCs (CiPSC) in China

In 2024–2025, researchers at Peking University, led by Dr. Hongkui Deng, reported a landmark achievement in the journal Cell Stem Cell. Using a revolutionary method called Chemical Reprogramming (CiPSC), they transformed a patient’s adult cells into pluripotent cells using only small-molecule chemicals, avoiding the genetic modifications used in traditional iPSC methods. This 

• Results: A 25-year-old female patient with T1D achieved complete insulin independence just 75 days after a CiPSC-islet transplant in her abdominal muscle. As of late 2025, she has remained injection-free for over a year with "normal" glucose levels.

2. Vertex Pharmaceuticals: The "Zimislecel" Breakthrough (USA)

In the United States, Vertex Pharmaceuticals has reported "unprecedented" results from its VX-880 (Zimislecel) program. Unlike the Chinese study, Vertex uses an allogeneic (donor) stem cell-derived islet therapy.

• Results: In Phase 1/2 trials, 10 out of 12 patients achieved complete insulin independence at the one-year mark. These results have been so consistent that Vertex is preparing for a formal global regulatory submission in 2026.
• Advancements: To eliminate the need for lifelong immunosuppressants, Vertex is also testing VX-264, which encapsulates these same cells in a protective device (the "cells-plus-device" approach), and exploring gene-edited "hypoimmune" cells to evade the immune system entirely.

A New Era for Regenerative Medicine and Industry

The implications of these approvals extend far beyond the patients who will soon have access to these therapies. For the pharmaceutical industry, they represent a proof-of-concept for the large-scale manufacturing and commercial viability of pluripotent stem cell treatments. While experimental iPS cell therapies have been administered in clinical trials for years, standardizing them into "off-the-shelf" products marks a definitive shift—bringing regenerative medicine out of the realm of research and into real-world patient care as a mainstream industrial sector.
Analysts predict that Japan's proactive regulatory environment could serve as a catalyst for global change. Other major markets, including the U.S. and EU, are expected to closely watch the real-world deployment of Amchepry and ReHeart, which may encourage them to accelerate their own frameworks for iPS-based therapies.
As Japan prepares for the formal rollout of these groundbreaking treatments, the global medical community will be intently observing the long-term durability of the therapies and their impact on healthcare costs and patient quality of life. For now, the country has firmly established itself as the global leader in translating the promise of iPS cell technology into tangible medical solutions.

References

AABB. (2026, February 24). Japanese regulatory panel recommends advancing world’s first iPSC-based therapies. 

https://www.aabb.org/news-resources/news/article/2026/02/24/japanese-regulatory-panel-recommends-advancing-world-s-first-ipsc-based-therapies

BioInformant. (2026, February 19). iPSC therapies make history: Japan authorizes world’s first two iPSC-based cell therapies. 

https://bioinformant.com/ipsc-therapies-make-history-japan-authorizes-worlds-first-two-ipsc-based-cell-therapies/

Breakthrough T1D Canada. (2025, March 28). Critical update: Vertex’s T1D cure trial progresses.

https://breakthrought1d.ca/tag/clinical-trial/

CiRA Foundation. (2025). Overview and history of iPS cell stocks. 

https://www.cira-foundation.or.jp/e/about/overview/

Deng, H., et al. (2024). Functional cure of a type 1 diabetes patient via chemically induced pluripotent stem cell-derived islets. Cell, 187(20). 

https://www.cell.com/cell/fulltext/S0092-8674(24)01022-X

FirstWord Pharma. (2025, June 21). ADA25: Most type 1 diabetes patients off insulin in Vertex's cell therapy trial. 

https://firstwordpharma.com/story/5975171

Kyodo News. (2026, February 19). Japan's Kansai region: A world hub for regenerative medicine. 

https://english.kyodonews.net/articles/-/70874

NHK World-Japan. (2026). iPS cells: Backstories. 

https://www3.nhk.or.jp/nhkworld/en/news/backstories/4613/

Nippon.com. (2026, February 19). Japan’s expert panel recommends approval of iPS cell-derived regenerative therapies. 

https://www.nippon.com/en/news/yjj2026021900704/

National Institutes of Health. (2019). Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent stem cells. PubMed Central (PMC). 

https://pmc.ncbi.nlm.nih.gov/articles/PMC6581764/

National Institutes of Health. (2025, January 10). Illuminating the future of diabetes treatment: Autologous CiPSC-derived islets take center stage. PubMed Central (PMC). 

https://pmc.ncbi.nlm.nih.gov/articles/PMC12357009/

Reuters. (2026, February 19). Japan government panel endorses Sumitomo Pharma’s iPS-derived treatment. 

https://www.reuters.com/business/healthcare-pharmaceuticals/japan-government-panel-endorses-sumitomo-pharmas-ips-derived-treatment-2026-02-19/

South China Morning Post. (2026). Japan approves world’s first regenerative medicines using iPS cells. 

https://www.scmp.com/news/asia/east-asia/article/3344036/japan-approves-worlds-first-regenerative-medicines-using-ips-cells

Vertex Pharmaceuticals. (2025). R&D pipeline: Type 1 diabetes. 

https://www.vrtx.com/our-science/pipeline/type-1-diabetes/